Biotech leaders back Pazdur for FDA as Takeda cuts 4,500 jobs

Summary

A massive coalition of hundreds of biotechnology executives and investors is throwing its support behind Rick Pazdur to become the next commissioner of the Food and Drug Administration, or FDA. The FDA is the federal agency responsible for ensuring that new medicines are safe and effective before they reach the public, and its top leadership sets the tone for how treatments are reviewed.

In other major industry news, the pharmaceutical company Takeda has announced a significant restructuring plan that will result in laying off 4,500 employees. At the same time, a biotech company called Alumis is halting the development of a once highly touted immunology drug, which is a type of medicine designed to interact with the immune system.

Because these updates are corporate news briefs rather than formal scientific studies, there are some important limitations to note. These reports offer a snapshot of business moves but do not include clinical data, patient sample sizes, or specific scientific insights into how the discontinued drugs were supposed to work in the body.

Why it matters.

These corporate shifts highlight the high stakes and constant volatility within the biotechnology and pharmaceutical sectors. The unified push by hundreds of investors and executives for a specific FDA commissioner shows just how important agency leadership is to the business of developing new medicines. The person in this role holds immense power over how clinical trials are run and how quickly life-saving therapies are approved for public use.

On the business side, Takeda eliminating 4,500 jobs and Alumis abandoning a major drug project reflect the harsh financial realities of medical research. Creating new medicines is an incredibly expensive and risky process. When companies face restructuring or when a highly anticipated drug is discontinued, the ripple effects are felt throughout the job market and patient communities, as these business decisions ultimately dictate which treatments make it to pharmacy shelves.

From the source

The story in numbers.

Workers to be laid off by Takeda: 4,500
Executives and investors campaigning: Hundreds

Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

The state of Maryland is taking a major step to rein in the cost of prescription medications. The Maryland Prescription Drug Affordability Board recently decided to set a strict price limit on Ozempic, a widely used treatment for type 2 diabetes. By establishing what is known as an upper payment limit, the board aims to make the medication more affordable for state budgets. Under this new rule, the cost of Ozempic will be capped at $274 for a standard 30-day supply. To come up with this number, the board looked at the maximum fair price that Medicare currently pays for the drug and used it as a benchmark. State officials estimate that this single price cap will save Maryland about $5.8 million every year. However, everyday consumers will not see these savings immediately. The initial price cap is slated to take effect in January 2027, and it will strictly apply to state and local government health plans. This means the immediate financial relief is limited to public programs rather than individual pharmacy visits for the general public.

STAT News1 min read

FDA shakeups, safety warnings, and a promising obesity pill

The Food and Drug Administration is navigating major leadership transitions, with acting directors Tracy Beth Høeg and Katherine Szarama recently exiting their roles in top drug review offices. Amidst these changes, the agency is facing severe safety concerns regarding Tavneos, a rare disease medication from the pharmaceutical company Amgen. In Japan, twenty patients taking the drug have died, with most of these deaths linked to a severe liver condition called vanishing bile duct syndrome. Following these tragedies and allegations of manipulated clinical trial data, the FDA has asked Amgen to withdraw the drug in the United States, though it currently remains available on the market. In other medical developments, an experimental daily pill for obesity is showing significant promise. Vincentage Pharma reported that patients taking its drug VCT220 in a late-stage Chinese clinical trial lost about twelve percent of their body weight over a year, compared to just one percent for those taking a placebo. However, the drug is still experimental globally, and a broader Phase 2 study is underway with results not expected until late 2026. Meanwhile, the major drugmaker Regeneron has teamed up with an early-stage startup called Parabilis Medicines. They plan to develop new therapies known as "antibody-helicon conjugates," which are designed to reach and treat disease-causing proteins inside cells that conventional methods have traditionally found impossible to target.

BioPharma Dive2 min read

Physical decline starts at 35, but late-in-life exercise boosts fitness

A massive study tracking people in Sweden for almost 50 years has pinpointed exactly when our bodies start to lose their physical edge. Researchers discovered that overall fitness, physical strength, and muscle endurance quietly begin to slip around age 35. Rather than maintaining a slow and steady pace, the researchers noted that the rate of this physical decline actually speeds up as the years go by. However, the study offers a highly encouraging twist for older adults. Even if someone has been inactive for decades, deciding to adopt a physically active lifestyle later in life can still yield major benefits. The researchers found that these late starters actually improved their physical performance by up to 10 percent, proving that the human body remains responsive to exercise well into old age. While tracking individuals over a five-decade span is a remarkable scientific achievement, there are a few limitations to keep in mind. The research is based entirely on a Swedish cohort, so it is unclear if these exact timelines apply to more diverse global populations. Additionally, the initial data does not specify the exact number of participants or the specific medical tests used to measure their fitness levels.

Science Daily1 min read

Follow your curiosity.

Biotech leaders back Pazdur for FDA as Takeda cuts 4,500 jobs

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

A little science goes a long way.